Navigation Links
Cancer vaccine impact limited unless drug industry focuses on difficult-to-treat tumors
Date:11/21/2011

Drug companies currently developing therapeutic cancer vaccines may be determining the cancers they target based on the number of annual cases, not the number of deaths they cause.

This approach may limit the patient benefits of such drugs, according to a new University of Michigan report.

Therapeutic vaccines, an alternative form of cancer treatment that may be more effective than traditional cancer therapies, are currently being tested in clinical trials around the world.

Early studies on these vaccines, which trigger patients' immune systems to attack cancer cells, have shown they may offer new hope for those suffering from difficult-to-treat cancers.

"In 2011, there were about 230 clinical trials for therapeutic vaccines targeting 13 different types of cancer," says Matthew Davis, M.D., M.A.P.P., associate professor of pediatrics, internal medicine, and public policy at the University of Michigan Health System and Gerald R. Ford School of Public Policy.

"If a cancer is more commonly diagnosed in the United States, it is significantly more likely to have therapeutic vaccines in clinical trials," Davis adds. "Focusing on annual incidence is a very common approach by drug companies in developing new therapies."

Therapeutic vaccine development should focus on cancers with higher mortality rates, creating more potential to improve patient outcomes, Davis suggests.

"The lack of a connection between therapeutic cancer vaccine development and cancer deaths means that vaccine development in this arena today may not best serve the needs of cancer patients tomorrow," Davis says. "As a primary care doctor, I would like to see innovations with therapeutic vaccines that target cancers where our current therapies are less effective than average."

Davis and co-author Elias Dayoub, a second-year medical student, emphasize that lung cancer and pancreatic cancer are two tumor types where the five-year survival is lower than average and the number of patients newly diagnosed each year is higher than average.

"Fortunately for patients, there are already some late-stage clinical trials in progress for patients with cancers of the lung and pancreas," Davis says. "Based on the typical time course for trials and licensure, if these vaccines are safe and effective, we may able to use them to help patients as early as 2020 and perhaps earlier."

The cancers with the highest number of active clinical trials worldwide in 2011 are melanoma (40), breast (34), lung (30), prostate (22), and brain (20).

The five cancers with the highest five-year mortality (estimated by the authors, based on current U.S. data) are lung (186,000), pancreas (40,000), colon (35,000), breast (21,000) and liver and bile duct (21,000), for a total of 303,000 deaths. There are currently 90 therapeutic vaccines in development against these 5 types of cancer.

In contrast, the five cancers with the most active development (146 vaccines in aggregate) target cancers with a lower five-year mortality of approximately 226,000. "This mismatch is unfortunate for patients," says Davis. "Cancers with higher mortality currently have fewer vaccines in development. For therapeutic vaccines to make the biggest difference in cancer care, development must focus more on high-mortality tumors."


'/>"/>

Contact: Lauren McLeod
lemcleod@med.umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Siblings Deeply Affected By Childs Cancer Death
2. Cancer drug cisplatin found to bind like glue in cellular RNA
3. New breast cancer screening guidelines released
4. BRAF addiction of thyroid cancers makes them therapeutically vulnerable
5. IBD patients face increased skin cancer risk
6. FDA Revokes Approval of Avastin for Breast Cancer
7. Colon cancer screening campaign erases racial, gender gaps in use of colonoscopy
8. Tender Breasts From Combo HRT Linked to Higher Cancer Risk
9. Combo hormone therapy has increased breast cancer risk over estrogen alone
10. PBX1 identified as a new pioneer factor underlying progression in breast cancer
11. Cancer Doctors Still Not Great With Patients Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business Capital, ... $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro ... facilitate a recapitalization of MedPro led by Harren Equity Partners. Brightwood Capital ...
(Date:1/19/2017)... ... 2017 , ... Workrite Ergonomics announced this week the launch ... panel system was designed to deliver the ideal blend of acoustic and visual ... the visual privacy required to maintain concentration levels and increase productivity. The tranquility ...
(Date:1/19/2017)... ... January 19, 2017 , ... Tribble Insurance Agency, a family owned and operated ... inaugurating a charity event to honor Chad Phillip Dermyer, a local police trooper who ... Phillip Dermyer and his fellow officers were conducting routine stops of suspects when one ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the second consecutive year, ... Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. Spencer Richlin, ... been chosen by their peers for the 2017 list based on their exceptional ...
(Date:1/19/2017)... Marriottsville, MD (PRWEB) , ... January 19, 2017 , ... ... launched six new clients into the US market. , Over the past 20 years ... the past 4 weeks SFI has launched six new clients into the US market. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017  Sensus Healthcare, ... device company specializing in the treatment of non-melanoma ... keloids, with superficial radiation therapy, today announced that ... year 2016 financial results on Thursday, February 2, 2017 ... will hold a conference call with the investment ...
(Date:1/19/2017)... England , January 19, 2017 ... and Otsuka in the Milner Therapeutics Consortium   ... scientists in Cambridge   ... (NYSE: PFE ) as a partner to ... the Consortium, which enables the efficient transfer of materials ...
(Date:1/19/2017)... NEW YORK , January 18, 2017 , , ... rd distribution agreement, following similar agreements ...   , Wound care is $2 5 ...   , E-QURE Corp. (OTCQB: EQUR), a leader in medical devices ... agreement with Tech - Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia ...
Breaking Medicine Technology: